12 Best Multibagger Stocks to Buy Heading into 2026

Page 8 of 11

4. Compass Therapeutics, Inc. (NASDAQ:CMPX)

Market Cap: $882.20 Million

Price Return over 1-Year: 224.18%

Upside Potential: 101.60%

Number of Hedge Fund Holders: 23

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 12 best multibagger stocks to buy heading into 2026.

On December 3, 2025, Compass Therapeutics, Inc. (NASDAQ:CMPX) saw Canaccord analyst John Newman initiate coverage of the stock with a “Buy” rating and a $10 price target. The analyst attributed the bullish stance to positive data in the first quarter of 2026 from second-line biliary tract cancer studies. Newman sees tovecimig as the central value driver, alongside additional clinical-stage assets that hold potential to support longer-term diversification.

Compass Therapeutics, Inc. (NASDAQ:CMPX) was also revisited by Citizens JMP analyst Reni Benjamin the same day, who initiated coverage with an “Outperform” rating and a $10 price target. Reported by The Fly, Benjamin cited recent data from a pivotal Phase 2/3 study. The data showed a 17% overall response rate for tovecimig in combination with paclitaxel in biliary tract cancers, versus 5% in the paclitaxel-only arm. This reinforces the program’s clinical momentum, the analyst noted.

In its Q3 2025 update, management provided further context on the therapy’s progress and confirmed that analyses of key secondary endpoints, including overall survival and progression-free survival from the COMPANION-002 Phase 2/3 trial, are expected to be reported in late Q1 2026 once the pre-specified event threshold is met. Compass Therapeutics, Inc. (NASDAQ:CMPX)’s management also confirmed that preparations are advancing for a Phase 2 basket study across multiple DLL4-positive tumors, alongside continued enrollment in an investigator-sponsored first-line combination trial.

Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage oncology biopharmaceutical company, develops proprietary antibody-based therapies, which target angiogenesis, immune activation, and tumor-driven immune suppression to treat multiple cancers.

Page 8 of 11